Evidence map›Paper›PMID 42288752›Full record

ArticleBMC cancer2026

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Jaume Capdevila, Virginia Pubul, Urbano Anido, Thomas Walter, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Rocio Garcia-Carbonero, Maria San-Roman-Gil, Belen Llana, Paula Jimenez-Fonseca and 25 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors.

Jaume CapdevilaMedical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. jcapdevila@vhio.net.
Virginia PubulDepartment of Nuclear Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
Urbano AnidoMolecular Imaging Research Group, Nuclear Medicine Department, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Thomas WalterMedical Oncology Department, Edouard Herriot Hospital, Lyon, France.
Javier Molina-CerrilloMedical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Teresa Alonso-GordoaMedical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Rocio Garcia-CarboneroMedical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Maria San-Roman-GilMedical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Belen LlanaNuclear Medicine Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Paula Jimenez-FonsecaMedical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain.
Marta Benavent ViñualesMedical Oncology Department, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain.
Catherine AnsquerService de Médecine Nucléaire, CHU de Nantes, Nantes Université, Nantes, France.
Eric BaudinDepartment of Endocrine Oncology and Nuclear Medicine, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
Come LepageDepartment of Digestive Oncology, University Hospital Dijon, University of Burgundy and Franche Comté, Dijon, France.
Maribel Del Olmo-GarcíaEndocrinology and Nutrition Department, Endocrinology, Nutrition and Diet Therapy, Research Unit, University and Polytechnic Hospital La Fe, Valencia, Spain.
José Carlos RuffinelliMedical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Amandine BeronService de Médecine Nucléaire, Hôpital Claude Huriez, CHU Lille, Lille, France.
Magalie HaissaguerreDepartment of Endocrinology, University of Bordeaux, Bordeaux, France.
Emmanuel DeshayesDepartment of Nuclear Medicine, Institut du Cancer de Montpellier, Université de Montpellier, Montpellier, Cedex 5, France.
David TaïebDepartment of Nuclear Medicine, Aix-Marseille University, La Timone University Hospital, Marseille, France.
Sergio BaldariNuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho‑Functional Imaging, University of Messina, Messina, Italy.
Maddalena SansoviniTherapeutic Nuclear Medicine, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) ''Dino Amadori'', Meldola, Italy.
Sara CingarliniMedical Oncology, University and Hospital Trust of Verona, Verona, Italy.
Angelina FiliceServizio Di Medicina Nucleare, Azienda USL-IRCCS Di Reggio Emilia, Reggio Emilia, Italy.
Francesco PanzutoDepartment of Medical‑Surgical Sciences and Translational Medicine, Sapienza University of Rome, Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy.
Rosa Álvarez-ÁlvarezMedical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
Laurence LousbergService d'Oncologie Médicale CHU Liège, Liège, Belgium.
Frank Aboubakar NanaDepartment of Pulmonology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, 1200, Belgium.
Jorge HernandoMedical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Alejando García-ÁlvarezMedical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Amparo García-BurilloMedical Oncology Department. Vall, Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Guillermo VillacampaStatistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Timon VandammeDepartment of Oncology and Netwerk, University Hospital Antwerp, Edegem, Belgium.
Nicola FazioDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
Alice DurandMedical Oncology Department, Edouard Herriot Hospital, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42288752
PMCPMC13264813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.